Novo Nordisk publishes results from OASIS 4 trial of Wegovy in NEJM

The New England Journal of Medicine published the results from the OASIS 4 phase 3 trial that studied the efficacy and safety of the investigational once-daily oral semaglutide 25 mg, or Wegovy. In the 64-week trial, oral semaglutide 25 mg, alongside lifestyle modifications, was compared to placebo in 307 adults with obesity or overweight with one or more weight-related comorbidities, without diabetes. Results showed that if all participants adhered to treatment, average weight loss of 16.6% was achieved by people taking oral semaglutide 25 mg compared to 2.7% for placebo at 64 weeks, with over a third experiencing a weight loss of 20% or more, versus 2.9% for placebo. This was comparable with previous trial results of injectable Wegovy. The safety and tolerability profile of oral semaglutide was consistent with that for injectable Wegovy. In the OASIS 4 trial, gastrointestinal adverse events with oral semaglutide 25 mg were generally mild to moderate in severity and transient; the most common of which were nausea and vomiting. Adverse events leading to permanent treatment discontinuation were 6.9% and 5.9%. The incidence of serious adverse events was 3.9% and 8.8%.